The hepatic flaviviridae: Summary

Journal of Viral Hepatitis

Volumn 6, Issue SUPPL. 1, 1999, Pages 1-5

  Sherlock, S ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Hepatitis C; Hepatitis G; Interferon; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; ENVELOPE PROTEIN; HEPATITIS VACCINE; INTERFERON; NEUTRALIZING ANTIBODY; RIBAVIRIN; VIRUS RNA;

ANTIBODY PRODUCTION; BLOOD TRANSFUSION; CHRONIC HEPATITIS; CONFERENCE PAPER; DISEASE TRANSMISSION; FLAVIVIRUS; HEPATITIS C VIRUS; HEPATITIS G VIRUS; HEPATITIS VIRUS; HUMAN; HUMORAL IMMUNITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINE PRODUCTION; VIRUS IMMUNITY;

ANIMALS; FLAVIVIRIDAE; HEPACIVIRUS; HEPATITIS C; HUMANS; MEMBRANE PROTEINS; RNA, VIRAL;

EID: 0032787830     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00007.x     Document Type: Article

References (50)

1. Martell M. Esteban JI, Quer J et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-3229.
2. Brambilla S, Bellati G, Asti M et al. Dynamics of hypervariable regions 1 variation in hepatitis G virus infection and correlation with clinical and virological features of liver disease. Hepatology 1998; 27: 1678-1686.
3. Hattori M, Yoshioka K, Aiyama T et al. Broadley reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: relation to viral loads and response to interferon. Hepatology 1998; 27: 1703-1710.
4. Enomoto N, Sakuma B, Asahina Y et al. Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
5. Fournillier A, Nakano I, Vitvitski L et al. Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmide DNA using single or combined delivery routes. Hepatology 1998; 28: 237-244.
6. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 1998; 72: 3827-3836.
7. Abrignani S. Immune responses throughout hepatitis C virus (HCV) infection. HCV from the immune system point of view. Springer Semin Immunopathol 1997; 19: 47055.
8. Nelson DR, Marousis CG, Ohno T et al. Intra-hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998; 28: 225-230.
9. Zavaglia C, Martinetti M, Silini E et al. Association between HLA class II alleles and protection from or susceptivility to chronic hepatitis C. J Hepatol 1998; 28: 1-7.
10. Burgio VL, Ballardini G, Artini M et al. Expression of co-stimulatory molecules by Kupffer cells in chronic hepatitis of hepatitis C etiology. Hepatology 1998; 27: 1600-1606.
11. Poynard T, bedossa P, Opolon P et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
12. Guadagnino V, Stroffolini T, Rapicetta M et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in Southern Italy. Hepatology 1997; 26: 1006-1011.
13. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C. A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
14. Roudot-Thoraval F, Bastie A, Pawlotsky J-M et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997; 26: 485-490.
15. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998; 28: 562-567.
16. Power JP, Lawlor E, Davidson F et al. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet 1995; 345: 1211.
17. Darby SC, Ewart DW, Giangrande PLF et al. Mortality from liver cancer and liver disease in haemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-1431.
18. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects Dose Duration Hepatology 1996; 24: 778-789.
19. Dhumeaux D, Doffoel M, Galmiche J-P. A French consensus conference on hepatitis C. Screening Treatment J Hepatol 1997; 27: 941-944.
20. National Institutes of Health consensus development conference panel statement. Management of hepatitis C. Hepatology 1997; 26 (Suppl. 1): 28-108.
21. Martinot-Peignous M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
22. Tong MJ, Blatt LM, McHutchison JG et al. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997; 26: 1620-1645.
23. Shiffman ML, Hofmann CM, Thompson EB et al. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 780-785.
24. Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intra-hepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Ann Intern Med 1997; 127: 875-881.
25. Camma C, Di Marco V, Iacono OL et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 531-537.
26. Kashara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-1402.
27. Zeuzem S, Schmidt JM, Lee J-H et al. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245-252.
28. Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997; 26: 961-966.
29. Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without interferon for chronic hepatitis C. Lancet 1998; 351: 83-87.
30. Ferenci P, Stauber R, Steindl-Munda P et al. Interim analysis of ribavirin and high-dose interferon-α in interferon nonresponders with chronic hepatitis C. J Viral Hep 1998; 6 (Suppl. 1): 53-58.
31. Simons JN, Leary TP, Dawson GJ et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995; 1: 564-569.
32. Linnen J, Wages J Jr, Zhang-Keek ZY et al. Molecular cloning and siease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 27: 505-508.
33. Kim JP, Fry KE. Characterization of the hepatitis G virus. J Viral Hep 1997; 4: 77-79.
34. Leary TP, Muerfoff S, Simons JN et al. Sequence and genomic organisation of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis. J Med Virol 1996; 48: 60-67.
35. Karayannis P, Thomas HC. Hepatitis G virus identification, prevalence and unanswered questions. Lancet 1997; 40: 294-296.
36. Tacke M, Kiyosawa K, Stark K et al. Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet 1997; 349: 318-320.
37. Feuchi H-H, Zollner B, Polywka S et al. Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients. Hepatology 1997; 26: 491-494.
38. Jarvis LM, Davidson F, Hanley JP et al. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996; 348: 1352-1355.
39. Masuko K, Mitsui T, Wano K et al. Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med 1996; 334: 1485-1490.
40. Viazov S, Riffelman M, Sarr S et al. Transmission of GBV-C/HGV from drug-addicted mothers to their babies. J Hepatol 1997; 27: 85-90.
41. Francesconi R, Giostra F, Ballardini G et al. Clinical implications of GBV-C/HGV infection in patients with 'HCV-related' chronic hepatitis. J Hepatol 1997; 26: 1165-1172.
42. Goeser T, Seipp S, Wah R et al. Clinical presentation of GB-C virus infection in drug abusers with chronic hepatitis C. J Hepatol 1997; 26: 498-502.
43. Heringlake S, Osterkamp S, Trautwein C et al. Association between fulminant hepatic failure and a strain of GBV-virus C. Lancet 1996; 348: 1626-1629.
44. Moaven LD, Locarnini SA, Bowden DS et al. Hepatitis G virus and fulminant hepatic failure. Evidence for transfusion-related infection. J Hepatol 1997; 27: 613-619.
45. Berg T, Dirla U, Naumann U et al. Responsiveness to interferon alpha treatment in patients with chronic hepatitis C coinfected with hepatitis G virus. J Hepatol 1996; 25: 763-768.
46. Martinot M, Marcellin P, Boyer N et al. Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alfa in patients with chronic hepatiits C. Ann Intern Med 1997; 126: 874-881.
47. Berenguer M, Terrault NA, Piatak M et al. Hepatitis G infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology 1996; 111: 1569-1575.
48. Haagsma EB, Cuypers TM, Gouw ASH et al. High prevalence of hepatitis G virus after liver transplantation without apparent influence on long-term graft function. J Hepatol 1997; 26: 921-925.
49. Fried MW, Khudyakov YE, Smallwood GA et al. Hepatitis G virus co-infection in liver transplantation recipients with chronic hepatitis C and non-viral chronic liver disease. Hepatology 1997; 25: 1271-1275.
50. Alter MJ, Gallagher M, Morris TT et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 1997; 336: 741-746.